References

nodgo

Российский журнал детской гематологии и онкологии (РЖДГиО)

Russian Journal of Pediatric Hematology and Oncology

2311-12672413-5496

LTD “Graphica”

10.21682/2311-1267-2023-10-2-92-98

nodgo-940

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

LITERATURE REVIEWS

Современные подходы к лечению рецидивов и рефрактерных форм гистиоцитоза из клеток Лангерганса. Обзор литературы

Modern approaches to the treatment of relapses and refractory forms of Langerhans cell histiocytosis. Literature review

https://orcid.org/0000-0001-9805-9972

Корнеева

М. С.

Korneeva

M. S.

Маргарита Сергеевна Корнеева, врач-гематолог отделения детской онкологии и гематологии (химиотерапия гемобластозов) № 2 НИИ детской онкологиии гематологии им. акад. РАМН Л.А. Дурнова,

115522, Москва, Каширское шоссе, 23

Hematologist Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 2 of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov,

23 Kashirskoe Shosse, Moscow, 115522

margokorneeva@mail.ru

https://orcid.org/0000-0002-3005-2085

Батманова

Н. А.

Batmanova

N. A.

к.м.н., заведующая отделением детской онкологии и гематологии (химиотерапия гемобластозов) № 2 НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова,

115522, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 2 of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov,

23 Kashirskoe Shosse, Moscow, 115522

batmanova_nataly@mail.ru

https://orcid.org/0000-0002-1469-2365

Валиев

Т. Т.

Valiev

T. T.

д.м.н., заведующий отделением детской онкологии и гематологии (химиотерапия гемобластозов) № 1 НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова,

115522, Москва, Каширское шоссе, 23

Dr. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov,

23 Kashirskoe Shosse, Moscow, 115522

timurvaliev@mail.ru

https://orcid.org/0000-0002-2945-284X

Киргизов

К. И.

Kirgizov

K. I.

к.м.н., заместитель директора по научной работе НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова,

115522, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work of Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov,

23 Kashirskoe Shosse, Moscow, 115522

k.kirgizov@ronc.ru

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian Federation

2023

19072023

1029298

2023

Корнеева М.С., Батманова Н.А., Валиев Т.Т., Киргизов К.И.

Korneeva M.S., Batmanova N.A., Valiev T.T., Kirgizov K.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nodgo.org/jour/article/view/940

Несмотря на высокие результаты лечения больных с впервые установленным диагнозом гистиоцитоза из клеток Лангерганса (ГКЛ), рецидивы отмечены у 29,9 % пациентов. Общепринятых стандартов терапии рецидивов и рефрактерных форм (р/р) ГКЛ в настоящий момент не существует. Прогноз пациентов, страдающих данной патологией, остается неблагоприятным. Современные подходы к терапии р/р ГКЛ включают использование BRAF- и MEK-ингибиторов, применение клеточных технологий лечения. В статье приведен литературный обзор актуальных подходов к лечению р/р ГКЛ на сегодняшний день и определены перспективы дальнейших исследований.

Despite of good outcomes in treatment of patients with newly diagnosed Langerhans cell histiocytosis (LCH), recurrences have been reported in 29.9 % of patients. There are currently no generally accepted standards for the treatment of recurrences and refractory forms of LCH. The prognosis of patients, suffering from this pathology, remains unfavorable. Current treatment approaches of recurrences and refractory forms of LCH include using of BRAF- and MEK-inhibitors and cellular treatment technologies. The article provides a literature review of current approaches to the treatment of recurrences and refractory forms of LCH and identifies the prospects for further research.

гистиоцитоз из клеток Лангергансарецидиврефрактерное течениелечениедети

langerhans cell histiocytosisrelapserefractory coursetreatmentchildren

References1

Karis J., Bernstrand C., Fadeel B., Henter J.-I. The incidence of langerhans cell histiocytosis in children in Stockholm Count, Sweden 1992–2001. In: Proceedings of the XIX meeting of the histiocyte society. Philadelphia, 2003. P. 21.

Monsereenusorn C., Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29:853–73. doi: 10.1016/j.hoc.2015.06.005.

Haupt R., Minkov M., Astigarraga I., Schäfer E., Nanduri V., Jubran R., Egeler R.M., Janka G., Micic D., Rodriguez-Galindo C., Van Gool S., Visser J., Weitzman S., Donadieu J.; Euro Histio Network. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–84. doi: 10.1002/pbc.24367.

Gadner H., Grois N., Arico M., Broadbent V., Ceci A., Jakobson A., Komp D., Michaelis J., Nicholson S., Pötschger U., Pritchard J., Ladisch S.; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138:728–34. doi: 10.1067/mpd.2001.111331.

Gadner H., Grois N., Potschger U., Minkov M., Aricò M., Braier J., Broadbent V., Donadieu J., Henter J.-I., McCarter R., Ladisch S.; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensifi cation. Blood. 2007;111:2556–62. doi: 10.1182/blood-2007-08-106211.

Minkov M., Grois N., Heitger A., Pötschger U., Westermeier T., Gadner H.; DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol. 2002;39:581–5. doi: 10.1002/mpo.10166.

Ronceray L., Potschger U., Janka G., Gadner H., Minkov M.; German Society for Pediatric Hematology and Oncology, Langerhans Cell Histiocytosis Study Group. Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: Eff ect on course and outcome. J Pediatr. 2012;161:129–33. doi: 10.1016/j.jpeds.2011.12.035.

Braier J., Latella A., Balancini B., Castaños C., Rosso D., Chantada G., Ripoli M., Goldberg J. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:765–9. doi: 10.1002/pbc.20112.

Евсеев Д.А., Калинина И.И., Ускова Н.Г., Самарин А.Е., Райкина Е.В., Салимова Т.Ю., Байдильдина Д.Д., Горонкова О.В., Митрофанова А.М., Масчан М.А., Масчан А.А. Применение превентивного плевродеза у пациента с гистиоцитозом из клеток Лангерганса с поражением легких. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(3):74‒80. doi: 10.24287/1726-1708-2018-17-3-74-80.

Evseev D.A., Kalinina I.I., Uskova N.G., Samarin A.E., Raykina E.V., Salimova T.Yu., Baydildina D.D., Goronkova O.V., Mitrofanova A.M., Maschan M.A., Maschan A.A. The use of preventive pleurodesis in patient with Langerhans-cell histiocytosis with lung involvement: the case report and the review. Voprosi gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2018;17(3):74‒80. (In Russ.). doi: 10.24287/1726-1708-2018-17-3-74-80.

Weitzman S., Egeler R.M. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008;20:23–9. doi: 10.1097/MOP.0b013e3282f45ba4.

Donadieu J., Chalard F., Jeziorski E. Medical management of Langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13:1309–22. doi: 10.1517/14656566.2012.688028.

Satter E.K., High W.A. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008;25:291–5. doi: 10.1111/j.1525-1470.2008.00669.x.

Grifo A.H. Langerhans cell histiocytosis in children. J Pediatr Oncol Nurs. 2009;26:41–7. doi: 10.1177/1043454208323915.

McClain K.L. Treatment of Langerhans cell histiocytosis. In: Post TW, editor. Up To Date. Waltham, MA. Accessed 22 June 2019.

Gadner H., Minkov M., Grois N., Pötschger U., Thiem E., Aricò M., Astigarraga I., Braier J., Donadieu J., Henter J.-I., Janka-Schaub G., McClain K.L., Weitzman S., Windebank K., Ladisch S.; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14. doi: 10.1182/blood-2012-09-455774.

Cui L., Wang C.J., Lian H.Y., Zhang L., Ma H.H., Wang D., Chen F.F., Zhang Q., Yang Y., Wei A., Huang X.T., Zhu T., Wang T.Y., Li Z.G., Zhang R. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study. Am J Hematol. 2023;98(4):598–607. doi: 10.1002/ajh.26829.

Donadieu J., Bernard F., van Noesel M., Barkaoui M., Bardet O., Mura R., Arico M., Piguet C., Gandemer V., Armari Alla C., Clausen N., Jeziorski E., Lambilliote A., Weitzman S., Henter J.I., Van Den Bos C.; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study. Blood. 2015;126:1415–23. doi: 10.1182/blood-2015-03-635151.

Veys P.A., Nanduri V., Baker K.S., He W., Bandini G., Biondi A., Dalissier A., Davis J.H., Eames G.M., Egeler R.M., Filipovich A.H., Fischer A., Jürgens H., Krance R., Lanino E., Leung W.H., Matthes S., Michel G., Orchard P.J., Pieczonka A., Ringdén O., Schlegel P.G., Sirvent A., Vettenranta K., Eapen M. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning. Br J Haematol. 2015;169:711–8. doi: 10.1111/bjh.13347.

Bernard F., Thomas C., Bernard Y., Munzer M., Parker J.L., Ouache M., Colin V.M., Perel Y., Chastagner P., Vermylen C., Donadieu J. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with hematological dysfunction. Eur J Cancer. 2005;41:2682–9. doi: 10.1016/j.ejca.2005.02.007.

Steinherz P.G., Meyers P.A., Steinherz L.J., Jeha S. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol. 2007;29:656–8. doi: 10.1097/MPH.0b013e318142b94b.

Abraham А., Alsultan А., Jeng М., Rodriguez-Galindo С., Campbell Р.К. Clofarabine Salvage Therapy for Refractory High-Risk Langerhans Cell Histiocytosis. Pediatr Blood Cancer 2013;60:e19–22. doi: 10.1002/pbc.24436.

Berres M.L., Lim K.P., Peters T., Price J., Takizawa H., Salmon H., Idoyaga J., Ruzo A., Lupo P.J., Hicks M.J., Shih A., Simko S.J., Abhyankar H., Chakraborty R., Leboeuf M., Beltrão M., Lira S.A., Heym K.M., Bigley V., Collin M., Manz M.G., McClain K., Merad M., Allen C.E. BRAF-V600E expression in precursor versus diff erentiated dendritic cells defi nes clinically distinct LCH risk groups. J Exp Med. 2014;211:669–83. doi: 10.1084/jem.20130977.

Badalian-Very G., Vergilio J.A., Degar B.A., MacConaill L.E., Brandner B., Calicchio M.L., Kuo F.C., Ligon A.H., Stevenson K.E., Kehoe S.M., Garraway L.A., Hahn W.C., Meyerson M., Fleming M.D., Rollins B.J. Recurrent BRAF Mutations in Langerhans Cell Histiocytosis. Blood 2010;116(11):1919–23. doi: 10.1182/blood-2010-04-279083.

Chakraborty R., Hampton O.A., Shen X., Simko S.J., Shih A., Abhyankar H., Lim K.P.H., Covington K.R., Trevino L., Dewal N., Muzny D.M., Doddapaneni H., Hu J., Wang L., Lupo P.J., Hicks M.J., Bonilla D.L., Dwyer K.C., Berres M.-L., Poulikakos P.I., Merad M., McClain K.L., Wheeler D.A., Allen C.E., Parsons D.W. Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. Blood 2014;124(19):3007–15. doi: 10.1182/blood-2014-05-577825.

Heritier S., Emile J.F., Barkaoui M.A., Thomas C., Fraitag S., Boudjemaa S., Renaud F., Moreau A., Peuchmaur M., Chassagne-Clément C., Dijoud F., Rigau V., Moshous D., Lambilliotte A., Mazingue F., Kebaili K., Miron J., Jeziorski E., Plat G., Aladjidi N., Ferster A., Pacquement H., Galambrun C., Brugières L., Leverger G., Mansuy L., Paillard C., Deville A., Armari-Alla C., Lutun A., Gillibert-Yvert M., Stephan J.-L., Cohen-Aubart F., Haroche J., Pellier I., Millot F., Lescoeur B., Gandemer V., Bodemer C., Lacave R., HéliasRodzewicz Z., Taly V., Geissmann F., Donadieu J. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to fi rst-line therapy. J Clin Oncol. 2016;34:3023–30. doi: 10.1200/JCO.2015.65.9508.

Heritier S., Emile J.F., Barkaoui M.A., Thomas C., Fraitag S., Boudjemaa S., Renaud F., Moreau A., Peuchmaur M., ChassagneClément C., Dijoud F., Rigau V., Moshous D., Lambilliotte A., Mazingue F., Kebaili K., Miron J., Jeziorski E., Plat G., Aladjidi N., Ferster A., Pacquement H., Galambrun C., Brugières L., Leverger G., Mansuy L., Paillard C., Deville A., Armari-Alla C., Lutun A., Gillibert-Yvert M., Stephan J.-L., Cohen-Aubart F., Haroche J., Pellier I., Millot F., Lescoeur B., Gandemer V., Bodemer C., Lacave R., HéliasRodzewicz Z., Taly V., Geissmann F., Donadieu J. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to fi rst-line therapy. J Clin Oncol. 2016;34:3023–30. doi: 10.1200/JCO.2015.65.9508.

Donadieu J., Larabi I.A., Tardieu M., Visser J., Hutter C., Sieni E., Kabbara N., Barkaoui M., Miron J., Chalard F., Milne P., Haroche J., Cohen F., Hélias-Rodzewicz Z., Simon N., Jehanne M., Kolenova A., Pagnier A., Aladjidi N., Schneider P., Plat G., Lutun A., Sonntagbauer A., Lehrnbecher T., Ferster A., Efremova V., Ahlmann M., Blanc L., Nicholson J., Lambilliote A., Boudiaf H., Lissat A., Svojgr K., Bernard F., Elitzur S., Golan M., Evseev D., Maschan M., Idbaih A., Slater O., Minkov M., Taly V., Collin M., Alvarez J.C., Emile J.F., Héritier S. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31):2857–65. doi: 10.1200/JCO.19.00456.

Brown N.A., Furtado L.V., Betz B.L., Kiel M.J., Weigelin H.C., Lim M.S., Elenitoba-Johnson K.S.J. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655–8. doi: 10.1182/blood-2014-05-577361.

Greaves W.O., Verma S., Patel K.P., Davies M.A., Barkoh B.A., Galbincea J.M., Yao H., Lazar A.J., Aldape K.D., Medeiros L.J., Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn. 2013;15(2):220–6. doi: 10.1016/j.jmoldx.2012.10.002.

Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., Dicara D., Ramos A.H., Lawrence M.S., Cibulskis K., Sivachenko A., Voet D., Saksena G., Stransky N., Onofrio R.C., Winckler W., Ardlie K., Wagle N., Wargo J., Chong K., Morton D.L., Stemke-Hale K., Chen G., Noble M., Meyerson M., Ladbury J.E., Davies M.A., Gershenwald J.E., Wagner S.N., Hoon D.S.B., Schadendorf D., Lander E.S., Gabriel S.B., Getz G., Garraway L.A., Chin L. A Landscape of Driver Mutations in Melanoma. Cell. 2012;150(2):251–63. doi: 10.1016/j.cell.2012.06.024.

Yang S., Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–7. doi: 10.3892/ol.2017.5557.

Se W.L., Mukherjee J. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. In: Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics and Immunotherapy, 2018. Pp. 323–332. doi: 10.1016/b978-0-12-812100-9.00022-x.

Yaeger R., Corcoran R.B. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–41. doi: 10.1158/2159-8290.CD-18-1321.

Бурцев Е.А., Бронин Г.О. МЕК-ингибиторы в терапии гистиоцитоза из клеток Лангерганса. Российский журнал детской гематологии и онкологии. 2022;9(3):42–7. doi: 10.21682/2311-1267-2022-9-3-42-47.

Burtsev E.A., Bronin G.O. MEK-inhibitors in treatment of Langerhans cell histiocytosis. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2022;9(3):42–7. (In Russ.). doi: 10.21682/2311-1267-2022-9-3-42-47.

Simko S.J., Tran H.D., Jones J., Bilgi M., Beaupin L.K., Coulter D., Garrington T., McCavit T.L., Moore C., Rivera-Ortegón F., Shaff er L., Stork L., Turcotte L., Welsh E.C., Hicks M.J., McClain K.L., Allen C.E. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai–Dorfman disease. Pediatr Blood Cancer. 2014;61:479–87. doi: 10.1002/pbc.24772.

The authors declare that there are no conflicts of interest present.